Close

Angel Medical Systems Receives CE Approval for its Device that Provide Early Warning of Heart Atack

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Who Is and Isn’t a Good Candidate for LASIK Surgery?

In the decades since its FDA approval, LASIK eye...

The Three Top Benefits of Opting for an Innovative Healthcare Practice

An innovative healthcare practice offers improved patient care through...

Remote Patient Monitoring: A Cost-Effective Solution for Patients and Health Facilities

Remote patient monitoring services are reshaping the healthcare landscape,...

PatientPoint improves health outcomes with new MyHealthTeam partnership

PatientPoint, one of the country’s leading digital health companies...
Hospital & Healthcare Management/ Healthcare News/ Device providing early warning of a heart attack/ Sept. 22 – Angel Medical Systems announced today that it has received CE (Conformite Europeenne) Mark approval for the commercial sale of The AngelMed Guardian System in Europe.  The Guardian System is an implantable early warning system designed to detect coronary occlusion from thrombotic events such as plaque ruptures and alert the patient, often before symptom onset.  The System is comprised of an internal implantable device about the size of a pacemaker with vibrational alerting.  The implant connects to the heart using a standard pacemaker lead.  External alerting is also provided by a pager-like external alerting device.

The CE Mark signals that a product is in compliance with all relevant EU legislation, making it eligible to be marketed and sold throughout the EU. The AngelMed Guardian is commercially available in Brazil and is currently being tested in the United States in the ALERTS Phase II Clinical Study under an investigational device exemption (IDE) from the FDA.

Dr. C. Michael Gibson of Harvard Medical School, who is leading the ALERTS study says, "Over the past two decades, it has routinely taken patients 2-3 hours to arrive at the hospital with a heart attack.  Our initial studies indicate that this device may reduce that time to approximately 20 minutes.  When time is muscle, every minute counts and our hope is that survival will be improved."

Dr. David Fischell, Chief Executive Officer of AngelMed adds, "Winning CE Mark approval in Europe offers a new avenue for our company to gain distribution, establish reimbursement networks, and to build relationships with thousands of cardiologists throughout the EU. The incidence of death from heart attacks is continuing to grow across Europe and the shortened time to treatment for heart attack that can result from early warning has the potential to reduce damage to the heart from heart attacks and save lives."

For more information on the AngelMed Guardian System or the ALERTS study, to go to http://www.angel-med.com.

SOURCE Angel Medical Systems

Latest stories

Related stories

Who Is and Isn’t a Good Candidate for LASIK Surgery?

In the decades since its FDA approval, LASIK eye...

The Three Top Benefits of Opting for an Innovative Healthcare Practice

An innovative healthcare practice offers improved patient care through...

Remote Patient Monitoring: A Cost-Effective Solution for Patients and Health Facilities

Remote patient monitoring services are reshaping the healthcare landscape,...

PatientPoint improves health outcomes with new MyHealthTeam partnership

PatientPoint, one of the country’s leading digital health companies...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back